TLR agonists were discussed in our book, including the potential beneficial use of TLRs in cancer. Imiquimod, a TLR-7, is a cream applied to the skin, which activates the immune system to attack in the area where it is applied. Imiquimod was shown to act against breast cancer topically, and to act against metastatic tumors. The application of Imiquimod likely programmed immune cells to attack cancer locally, and then the re-programmed immune cells spread systemically to attack metastatic cancer. We have advocated for more extensive and creative uses of TLR agonists in cancer, including in conjunction with other necessary surgery and/or cancer treatment.

CAR T-cell therapy is a cancer treatment given in combination with various types of TLR agonists. The combined treatment is showing promising results in the treatment of many types of cancer.

Sometimes, we already have drugs available that are overlooked as potential treatments in chronic disease.

https://pubmed.ncbi.nlm.nih.gov/23172886/

https://pubmed.ncbi.nlm.nih.gov/22767669/

https://pubmed.ncbi.nlm.nih.gov/19380767/

https://www.hindawi.com/journals/jir/2021/9912188/